For example, knocking out of the Fc Fragment of IgG receptor isoforms (FCGR1A, FCGR2B, and FCGR3a)– which are required for the manifestation of antibody-dependent cellular cytotoxicity and anti-angiogenic activity of bevacizumab [33], which targets the vascular endothelial growth factor receptor (VEGFR) in ovarian, intestinal, and kidney cancers, did not influence the cancer cell fitness (Figure 2C). Here, FCGR2B is linked to cancer.